Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248602 | 1.00 | P2RX7 (1.00) | P2RX7PTGS2 | |
| SCHEMBL3248604 | 1.00 | P2RX7 (1.00) | P2RX7PTGS2 | |
| Trifluoroacetic Acid SCHEMBL3254060 | 0.90 | P2RX7 (0.81) | P2RX7PTGS2 | |
| Trifluoroacetic Acid SCHEMBL3254056 | 0.90 | P2RX7 (0.81) | P2RX7PTGS2 | |
| SCHEMBL13298611 | 0.89 | P2RX7 (0.80) | P2RX7PTGS2 | |
| SCHEMBL3265787 | 0.89 | P2RX7 (0.80) | P2RX7PTGS2 | |
| SCHEMBL3257128 | 0.87 | P2RX7 (0.81) | P2RX7 | |
| SCHEMBL3257124 | 0.87 | P2RX7 (0.81) | P2RX7 | |
| SCHEMBL3257125 | 0.87 | P2RX7 (0.81) | P2RX7 | |
| SCHEMBL3256650 | 0.87 | P2RX7 (0.76) | P2RX7PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | claimed |
| JP-2006528178-A | — | — | 2006-12-14 | — | — | JP | claimed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | claimed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | claimed |
| US-7741493-B2 | 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives; antiinflammatory agent, neurodegenerative diseases; inflammatory bowel disease, rheumatoid arthritis and diseases associated with central nervous system, such as Alzheimer's disease | AVENTIS PHARMACEUTICALS INC. (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1651613-B1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMA INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-7326792-B2 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1651613-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | Aventis Pharmaceuticals, Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014555-A1 | 4,5-DIHYDRO-IMIDAZOLE AS P2X7 ION CHANNEL BLOCKERS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | AVENTIS PHARMACEUTICALS INC. (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132550-A1 | HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS | P2RX3, P2RX2, P2RX5 | P2RX7 5/4885PTGS2 493/4885 |
| US-20050026916-A1 | Heterocyclic compounds as P2X7 ion channel blockers | P2RX3, P2RX2, P2RX5 | P2RX7 5/4885PTGS2 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.